Lercanidipin Sandoz (Lercanidipine Hydrochloride)

Lercanidipine acts on the vascular smooth‑muscle calcium channels to lower blood pressure in hypertensive patients.

• Essential hypertension: reduces systolic and diastolic blood pressure by arterial vasodilation.
• Primary hypertension: improves blood pressure control when used as monotherapy or in combination.
• Secondary hypertension: assists in managing elevated pressure due to identifiable causes when other treatments are insufficient.

• Lercanidipine selectively inhibits L‑type calcium channels in vascular smooth muscle, preventing calcium influx that is necessary for contraction. This inhibition leads to relaxation of arterial smooth muscle, resulting in vasodilation, decreased peripheral vascular resistance, and ultimately a reduction in systemic blood pressure.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate intensity, often occurring early in therapy.
• Flushing: warmth and redness of the skin, typically on the face or neck.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness or light‑headedness, especially when standing quickly.
• Fatigue: general feeling of tiredness without exertion.
• Tachycardia: increased heart rate, usually mild.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that may cause fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Angioedema: swelling of the face, lips, tongue, or throat requiring urgent care.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Severe bradycardia: markedly slow heart rate.
• Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy with Lercanidipine, several safety considerations should be reviewed.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: use with caution; liver disease may alter drug metabolism.
• Concomitant antihypertensives: risk of additive blood‑pressure lowering effects.
• Elderly patients: increased susceptibility to orthostatic hypotension; start at low dose.
• Pregnancy: safety not established; avoid unless clearly needed.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Lercanidipine can interact with several drug classes, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Other calcium‑channel blockers: additive vasodilatory effect leading to hypotension.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may enhance bradycardia or AV‑block.

• Diuretics: can increase risk of electrolyte imbalance and orthostatic hypotension.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.